Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
About Clearmind Medicine Inc. (CMND)
Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0) is a clinical-stage psychedelic pharmaceutical biotechnology company pioneering the development of novel psychedelic-derived therapeutics to address widespread and underserved health challenges. With a focus on non-hallucinogenic compounds, Clearmind aims to transform the treatment landscape for conditions such as alcohol use disorder (AUD), binge behavior, and other mental health disorders.
Innovative Therapeutic Solutions
The company’s flagship therapeutic, MEAI (5-methoxy-2-aminoindane), is a groundbreaking psychoactive molecule designed to regulate binge behaviors, including alcohol consumption, while providing a mild euphoric experience. MEAI-based treatments, such as CMND-100, are currently undergoing clinical trials to evaluate their safety, tolerability, and efficacy. Clearmind’s Phase I/IIa clinical trials, conducted in collaboration with leading institutions like Yale School of Medicine and Johns Hopkins University, underscore its commitment to rigorous scientific validation.
Expanding Intellectual Property Portfolio
Clearmind boasts an extensive and growing intellectual property (IP) portfolio, comprising 31 granted patents across 19 patent families, with protections secured in key jurisdictions such as the U.S., Europe, China, and India. This robust IP strategy covers innovative compounds, combination therapies, and delivery methods, ensuring the company’s competitive edge in the psychedelic pharmaceutical space. Recent patents include novel combinations of MEAI with N-Acylethanolamines and other compounds to enhance therapeutic efficacy and safety.
Collaborative Approach
Collaboration is central to Clearmind’s innovation strategy. The company partners with academic institutions like the Hebrew University of Jerusalem through Yissum Research Development Company and pharmaceutical firms such as SciSparc Ltd. These partnerships enable the development of next-generation psychedelic therapies targeting complex conditions like post-traumatic stress disorder (PTSD), opioid use disorder (OUD), and more.
Market Potential and Social Impact
Clearmind operates within the rapidly growing psychedelic therapeutics market, driven by increasing recognition of psychedelics’ potential in mental health treatment. The global market for AUD and PTSD treatments alone represents billions in unmet demand. Clearmind’s innovative solutions, such as its MEAI-based alcohol alternative developed in collaboration with Dr. Glitter Pty Ltd, aim to address these gaps by offering safer, non-addictive alternatives to traditional treatments.
Commitment to Safety and Accessibility
Clearmind’s therapeutic pipeline emphasizes safety and accessibility. By focusing on non-hallucinogenic psychedelic compounds, the company seeks to minimize risks while maximizing therapeutic benefits. This approach aligns with its mission to improve quality of life for patients worldwide, particularly those struggling with addiction and mental health disorders.
Future Outlook
As a pioneer in the psychedelic pharmaceutical industry, Clearmind Medicine Inc. is well-positioned to lead the next wave of innovation in mental health and addiction treatment. Its strategic focus on intellectual property, clinical validation, and collaborative partnerships underscores its potential to revolutionize the field and deliver transformative solutions to global healthcare challenges.
Clearmind Medicine (Nasdaq: CMND) has received a Notice of Allowance from the United States Patent Office for a patent covering its MEAI treatment for binge behavior. This development strengthens the company's intellectual property portfolio and provides additional protection for their novel MEAI-based treatment.
The clinical-stage biotech company, which focuses on developing psychedelic-derived therapeutics for major under-treated health problems, views this patent allowance as a important step in supporting their future success and advancing next-generation psychedelic-derived therapeutics aimed at delivering transformative patient outcomes.
Clearmind Medicine (NASDAQ: CMND) has launched its Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived treatment for Alcohol Use Disorder (AUD), at Johns Hopkins University School of Medicine. The trial will also be conducted at Yale School of Medicine and IMCA Center in Israel.
The study aims to evaluate the safety, tolerability, and pharmacokinetics of CMND-100, with preliminary efficacy assessments focusing on alcohol craving and consumption reduction. The trial represents the first clinical application of Clearmind's proprietary MEAI-based oral drug platform.
The study will be led by Jennifer Ellis, PhD, and Professor Eric Strain at Johns Hopkins. This initiative addresses a significant global health challenge, as WHO reports approximately 400 million people suffer from alcohol use disorders, with 209 million experiencing alcohol dependence. Alcohol contributes to 2.6 million deaths annually, representing 4.7% of global deaths, with 13% occurring among those aged 20-39.
Clearmind Medicine (NASDAQ: CMND) has initiated its Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived treatment for Alcohol Use Disorder (AUD), at Johns Hopkins University School of Medicine. The trial will also be conducted at Yale School of Medicine and IMCA Center in Israel.
The study aims to evaluate the safety, tolerability, and pharmacokinetics of CMND-100 in AUD patients, including preliminary efficacy assessments for reducing alcohol cravings and consumption. CMND-100 is a proprietary MEAI-based oral drug candidate designed to modulate reward mechanisms associated with addictive behavior.
The trial's significance is underscored by global AUD statistics: 400 million people aged 15 and older live with alcohol use disorders, with 209 million experiencing alcohol dependence. Alcohol contributes to 2.6 million deaths annually (4.7% of global deaths), with 13% occurring among ages 20-39. In the US, 15.1% of adults aged 18-25 met past-year AUD criteria according to the 2023 NSDUH.
Clearmind Medicine (Nasdaq: CMND) has announced the publication of an international patent application for novel psychedelic-based compounds, developed in collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The patent application focuses on innovative compounds designed to treat mental health disorders and addiction.
The announcement, made on April 08, 2025, represents a significant advancement in Clearmind's mission to develop next-generation psychedelic-derived therapeutics. These new '3.0 compounds' are designed to overcome limitations of classical psychedelics while providing safe and effective solutions for under-treated mental health conditions.
The patent is part of Clearmind's exclusive worldwide licensing agreement with Yissum, encompassing the development, research, manufacturing, marketing, and commercialization of products derived from patent-pending psychedelic compound synthesis.
Clearmind Medicine (Nasdaq: CMND) has launched its Electronic Data Capture (EDC) system for its Phase I/II clinical trial evaluating a MEAI-based treatment for Alcohol Use Disorder (AUD). The EDC system represents a important operational milestone, enabling:
- Real-time, secure data collection across study sites
- Automated edit checks and validation
- Secure randomization process
- Accurate tracking of safety events
- Informed consent procedures
- Proper patient allocation between study arms
The clinical trial aims to assess the safety, tolerability, and efficacy of Clearmind's psychedelic-derived, MEAI-based compound in individuals with alcohol addiction. The system includes separate notification flows for blinded and unblinded staff to maintain protocol compliance and trial integrity.
Clearmind Medicine (Nasdaq: CMND) has reached a significant milestone as its drug candidate CMND-100 arrives in the United States, preparing for its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) treatment.
The clinical trial will evaluate CMND-100, a proprietary MEAI-based oral drug candidate, for safety and efficacy in reducing alcohol consumption. The study will be conducted at prestigious institutions including Yale School of Medicine's Department of Psychiatry, Johns Hopkins University School of Medicine, and IMCA in Ramat Gan, Israel.
The company is targeting a significant market opportunity, as AUD affects over 28 million adults in the U.S., with an estimated global market potential of $35 billion. CMND-100 aims to reduce alcohol consumption and cravings through a novel mechanism of action.
Clearmind Medicine (Nasdaq: CMND) has signed a non-binding Letter of Intent with Polyrizon (Nasdaq: PLRZ) to develop a novel intranasal formulation for its psychedelic-based treatments. The collaboration aims to enhance the delivery of Clearmind's proprietary drug candidate, 5-Methoxy-2-aminoindane (MEAI), alone or combined with Palmitoylethanolamide (PEA).
The partnership focuses on developing an intranasal delivery system that could offer several advantages including:
- Faster absorption and onset of action
- Higher bioavailability for increased therapeutic effects
- Enhanced patient compliance through non-invasive administration
Under the agreement, Clearmind will fund the R&D process, while Polyrizon will advance formulation development using its proprietary intranasal drug delivery platform. Upon successful proof of concept, the parties plan to negotiate a definitive agreement covering IP rights, commercialization, and financial terms.
Clearmind Medicine (Nasdaq: CMND) has initiated its Phase I/IIa clinical trial for CMND-100, marking its transition to a clinical-stage pharmaceutical company. The trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100 in Alcohol Use Disorder (AUD) patients.
The study will be conducted at three prestigious institutions: IMCA in Israel, led by Prof. Mark Weiser, Yale School of Medicine's Department of Psychiatry, and Johns Hopkins University School of Medicine. The trial will also assess preliminary efficacy in reducing alcohol cravings and consumption.
CMND-100 is the company's proprietary MEAI-based oral drug candidate, designed to offer a novel approach by modulating reward mechanisms associated with addictive behavior. This represents a potential breakthrough in addressing the global AUD crisis, which affects approximately 400 million people worldwide and contributes to 2.6 million deaths annually according to WHO data.
Clearmind Medicine (NASDAQ: CMND) has secured a patent publication in South Korea for its innovative combination therapy using MEAI and N-Acylethanolamines to treat cocaine addiction. The patent is based on successful preclinical trials conducted at Bar-Ilan University's Gonda Multidisciplinary Brain Research Center in Israel.
The research demonstrated that animals treated with MEAI showed significant reduction in cocaine-induced cravings while maintaining normal responses to natural rewards like sucrose. This suggests MEAI specifically targets drug-related compulsions without affecting the general reward system.
The development is part of Clearmind's collaboration with SciSparc (NASDAQ: SPRC), combining Clearmind's MEAI psychedelic treatment with SciSparc's PEA for addiction and mental health applications. Multiple patent applications have been filed in the U.S. and other global jurisdictions.
Clearmind Medicine (Nasdaq: CMND) has announced the publication of a patent by Mexico's National Patent Office (IMPI) for its combination therapy treatment. The patent covers an innovative treatment combining MEAI and N-Acylethanolamines, targeting various binge behaviors including alcohol, eating, tobacco, shopping, and sexual conduct.
The patent emerged from Clearmind's collaboration with SciSparc (Nasdaq: SPRC), focusing on developing treatments for central nervous system disorders. The partnership aims to research combination therapies that integrate psychedelic compounds with N-Acylethanolamines family, including Palmitoylethanolamide (PEA).
FAQ
What is the current stock price of Clearmind Medici (CMND)?
What is the market cap of Clearmind Medici (CMND)?
What does Clearmind Medicine Inc. specialize in?
What is MEAI and how is it used?
What is Clearmind’s approach to intellectual property?
Who are Clearmind’s key collaborators?
What market needs does Clearmind address?
How does Clearmind ensure safety in its treatments?
What is Clearmind’s alcohol alternative product?
What differentiates Clearmind from competitors?
